


**ALLIANCEBERNSTEIN®**
**OVERALL MORNINGSTAR RATING™**

Class I USD Shares



Rated against 297 funds in the Sector Equity Health Care Category, based on risk-adjusted returns.

## AB INTERNATIONAL HEALTH CARE PORTFOLIO

### STRATEGY

Seeks growth of capital by:

- + Investing primarily in equity securities of health care and health care-related companies located throughout the world
- + Employing rigorous bottom-up research to identify companies with long-term growth potential in various market conditions by focusing on those with a history of high returns on invested capital, strong free cash flows and attractive valuations
- + Emphasizing companies that are expected to attract health care spending, generally through the introduction of new treatments and therapies or by offering customers cost reduction opportunities

### PROFILE


The Portfolio will suit higher-risk-tolerant investors seeking the medium- to long-term rewards of equity investment.

- + **Fund Inception:** 05/07/1995
- + **Domicile:** Luxembourg
- + **Fiscal Year-End:** 31 May
- + **Subscription/Redemption:** Daily
- + **Net Assets:** \$901.24 million
- + **Total # of Holdings:** 41
- + **Active Share:** 62%
- + **Order Placement Cutoff Time:** 4PM US ET
- + **Base Currency:** US Dollar
- + **Reporting Currencies:** Euro
- + **Benchmark:** MSCI World Health Care Index<sup>1</sup>
- + **Fund Type:** SICAV I

### PORTFOLIO MANAGEMENT & EXPERIENCE

- + **John H. Fogarty, CFA:** 26 years
- + **Vinay Thapar:** 19 years

### RISK & REWARD PROFILE



This synthetic risk and reward indicator (SRRI) scale rating indicates how the Portfolio may perform and the risk of losing some or all of your capital. The SRRI is from the most recent KIID, available from our website, and may be subject to change.

### GROWTH OF \$10,000



**Past performance does not guarantee future results.** The performance shown above is net of ongoing charges and assumes an investment of \$10,000 at inception of the share class. Other personal securities account costs (e.g., custody fees) may additionally reduce performance.

### PERFORMANCE (RETURNS ARE ANNUALIZED FOR PERIODS LONGER THAN ONE YEAR)

Class	1 Month	YTD	1 Year	3 Years	5 Years	10 Years	Since Inception
I	1.59%	21.05%	21.05%	17.22%	10.78%	11.80%	6.77%
Benchmark	3.41	23.24	23.24	14.82	8.50	12.29	6.71 <sup>2</sup>

**Past performance does not guarantee future results.**

### CALENDAR YEAR PERFORMANCE

Class	2015	2016	2017	2018	2019
I	8.76 %	-4.76%	26.60%	5.10%	21.05%
Benchmark	6.60	-6.81	19.80	2.51	23.24

**Past performance does not guarantee future results.** The value of investments and the income from them will vary. Your capital is at risk. Performance data are provided in the share class currency, and include the change in net asset value and the reinvestment of any distributions paid on Portfolio shares for the period shown. Performance data are net of management fees, but do not reflect sales charges or the effect of taxes. Returns for other share classes will vary due to different charges and expenses.

### SHARE CLASS INFORMATION

Class	ISIN	Bloomberg	Valoren	Inception	Dist. Yield <sup>3</sup>	Dividend <sup>4</sup>	Net Asset Value <sup>5</sup>
I	LU0097089360	ACMHCI:LX	0634213	18/02/1999	-	-	458.39

Source: AllianceBernstein (AB).

**FEES & CHARGES**

Class	Max Entry Charge <sup>6</sup>	Exit Charge	Ongoing Charge	Performance Fee
I	1.50%	None	1.21%	None

Ongoing charges include fees and certain expenses of the Portfolio as of the most recent KIID, and may be subject to a cap which is reflected above if applicable. Full details of the charges are available in the Portfolio's prospectus.

**HOLDINGS & ALLOCATIONS**

Top Ten Holdings	Industry	Holding
Roche	Pharmaceuticals	9.13%
UnitedHealth Group	Health Care Providers & Services	8.94
Pfizer	Pharmaceuticals	6.78
Vertex Pharmaceuticals	Biotechnology	4.54
Cigna	Health Care Providers & Services	4.35
Zoetis	Pharmaceuticals	3.95
Intuitive Surgical	Health Care Equipment & Supplies	3.77
Medtronic	Health Care Equipment & Supplies	3.74
GlaxoSmithKline	Pharmaceuticals	3.54
AstraZeneca	Pharmaceuticals	3.37
<b>Total</b>		<b>52.11</b>

Industry Allocation	
Pharmaceuticals	35.79%
Health Care Equipment & Supplies	22.81
Health Care Providers & Services	17.38
Biotechnology	12.12
Life Sciences Tools & Services	5.29
Health Care Technology	0.93
Cash & Other	5.68

Country Allocation	
United States	66.13%
Switzerland	13.32
United Kingdom	7.69
Denmark	4.50
Japan	2.26
Australia	2.07
France	0.99
United Arab Emirates	0.88
Germany	0.78
Brazil	0.54
Other	0.84

Source: AllianceBernstein (AB). Portfolio holdings and weightings are subject to change.

1 The MSCI World Health Care Index is a free float-adjusted market capitalization index that is designed to measure global developed market equity performance for the Health Care Sector. The MSCI World Health Care Index consists of 23 developed market country indices. An investor cannot invest directly in an index, and their results are not indicative of the performance for any specific investment, including an AB fund. Indices do not include sales charges or operating expenses associated with an investment in a mutual fund, which would reduce total returns.

2 Since inception performance is from closest month-end after inception date of oldest class shown. See page 1 for inception dates.

3 Yields are calculated based on the latest available distribution rate per share for a particular class. The yield is not guaranteed and will fluctuate.

4 For distributing classes, a Portfolio may pay dividends from gross income (before reduction for fees and expenses), realized and unrealized gains, and capital attributable to the relevant class. Investors should note that distributions in excess of net income (gross income less fees and expenses) may represent a return of the investor's original investment amount and as such may result in a decrease in the net asset value per unit for the relevant class. Distributions out of capital may be taxed as income in certain jurisdictions.

5 Net asset value is denominated in the share class currency.

6 This is the maximum figure; the entry charge may be less than this.

**INVESTMENT RISKS TO CONSIDER** These and other risks are described in the Portfolio's prospectus.

**Investment in the Portfolio entails certain risks.** Investment returns and principal value of the Portfolio will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Some of the principal risks of investing in the Portfolio include:

**Emerging-Markets Risk:** Where the Portfolio invests in emerging markets, these assets are generally smaller and more sensitive to economic and political factors, and may be less easily traded, which could cause a loss to the Portfolio.

**Focused Portfolio Risk:** Investing in a limited number of issuers, industries, sectors or countries may subject the Portfolio to greater volatility than one invested in a larger or more diverse array of securities.

**Allocation Risk:** The risk that the allocation of investments between growth and value companies may have a more significant effect on the Portfolio's Net Asset Value (NAV) when one of these strategies is not performing as well as the other. In addition, the transaction costs of rebalancing the investments may, over time, be significant.

**Portfolio Turnover Risk:** A portfolio may be actively managed and turnover may, in response to market conditions, exceed 100%. A higher rate of portfolio turnover increases brokerage and other expenses. High portfolio turnover may also result in the realization of substantial net short-term capital gains, which may be taxable when distributed.

**Derivatives Risk:** The Portfolio may include financial derivative instruments. These may be used to obtain, increase or reduce exposure to underlying assets and may create gearing; their use may result in greater fluctuations of the net asset value.

**OTC Derivatives Counterparty Risk:** Transactions in over-the-counter (OTC) derivatives markets may have generally less governmental regulation and supervision than transactions entered into on organized exchanges. These will be subject to the risk that its direct counterparty will not perform its obligations and that the Portfolio will sustain losses.

**Equity Securities Risk:** The value of equity investments may fluctuate in response to the activities and results of individual companies or because of market and economic conditions. These investments may decline over short- or long-term periods.

Dividends are not paid for all share classes and are not guaranteed. The Portfolio is meant as a vehicle for diversification and does not represent a complete investment program. Before making an investment decision, prospective investors should read the prospectus carefully and discuss risk and the Portfolio's fees and charges with their financial adviser to determine if the investment is appropriate for them. This financial promotion is directed solely at persons in jurisdictions where the funds and relevant share class are registered or who may otherwise lawfully receive it. Investors should review the Portfolio's full Prospectus, together with the Portfolio's Key Investor Information Document and the most recent financial statements. Copies of these documents, including the latest annual report and, if issued thereafter, the latest semi-annual report, may be obtained free of charge from AllianceBernstein (Luxembourg) S.à r.l. by visiting [www.alliancebernstein.com](http://www.alliancebernstein.com), or in printed form by contacting the local distributor in the jurisdictions in which the funds are authorised for distribution.

Investors are encouraged to consult their independent financial advisors regarding the suitability of Shares of the Portfolio for their investment needs.

**Past performance does not guarantee future results.**

The actual return achieved by investors in other currencies may increase or decrease as a result of currency fluctuations. Currency-hedged share classes use hedging techniques in an attempt to reduce—but not eliminate—fluctuations between the investor's holdings in a particular currency-hedged share class denominated in the investor's investing currency and the Portfolio's base currency. The goal is to deliver returns that track the Portfolio's base currency returns more closely.

**Note to European Readers:** The Key Investor Information Document is available in the local language of each country in which the Fund is registered. The Fund's Prospectus is available in English, French and German. This information is issued by AllianceBernstein Limited, 50 Berkeley Street, London W1J 8HA. Registered in England, No. 255 1 144. AllianceBernstein Limited is authorised and regulated in the UK by the Financial Conduct Authority (FCA).

**Note to Austrian and German Readers:** Local paying and information agents: Austria—UniCredit Bank Austria AG, Schottengasse 6-8, 1010 Vienna; Germany—ODDO BHF Aktiengesellschaft, Bockenheimer Landstraße 10, 60323 Frankfurt am Main.

**Note to Italian Readers: For Investment Professional use only.**

**Note to Liechtenstein Readers:** The Fund is not registered for public distribution in Liechtenstein and, accordingly, shares may only be offered to a limited group of Professional Investors, in all cases and under all circumstances designed to preclude a public solicitation in Liechtenstein. This fact sheet may not be reproduced or used for any other purpose, nor be furnished to any person other than those to whom copies have personally been sent by AB. Neither the Fund nor the shares described therein have been subject to the review and supervision of the Liechtenstein Financial Market Authority.

**Note to Swiss Readers:** This document is issued by AllianceBernstein Schweiz AG, Zurich, a company registered in Switzerland under company number CHE-306.220.501. AllianceBernstein Schweiz AG is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA) as a distributor of collective investment schemes. Swiss Representative & Swiss Paying Agent: BNP Paribas Securities Services, Paris, Succursale de Zürich. Registered office: Selnaustrasse 16, 8002 Zürich, Switzerland, which is also the place of performance and the place of jurisdiction for any litigation in relation to the distribution of shares in Switzerland. The Prospectus, the key investor information documents, the Articles or management regulations, and the annual and semiannual reports of the concerned fund may be requested without cost at the offices of the Swiss representative.

Overall Morningstar Rating is a copyright of Morningstar, Inc., 2020. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Shares of AB funds are offered only pursuant to the current prospectus together with the most recent financial statements. The information on this page is for information purposes only and should not be construed as an offer to sell, or solicitation of an offer to buy, or a recommendation for the securities of any AB fund.

